<DOC>
	<DOCNO>NCT00215761</DOCNO>
	<brief_summary>Comparison AF-Burden patient paroxysmal atrial fibrillation necessity Dual-Chamber-Pacemaker-Therapy either DDD [ R ] 60-Stimulation AF prevention pace . All Patients stratify accord exist drug therapy , e.g . Beta-Blocker ACE-Inhibitor .</brief_summary>
	<brief_title>Recurrence Atrial Fibrillation Patients With Dual-chamber Pacemakers Drug Therapy</brief_title>
	<detailed_description>Implantable pacemaker device available specific atrial pacing algorithm design prevent atrial arrhythmia ( Preventive stimulation ) . These algorithms work increase atrial pacing rate achieve continuous overdrive pace respond trigger premature atrial complex . Different investigation 's show preventive atrial pacing associate 30 50 % reduction risk recurrence AF , compare pacing . But complete recurrence-free long-term effect reach . A hybrid therapy consist combination preventive atrial stimulation pharmacologic therapy maybe useful restore sinus rhythm . The HOPE- ( Heart Outcomes Prevention Evaluation ) -Trial show overwhelming evidence , broad range high-risk patient , ACE-Inhibitor ( Ramipril ) prevent cardiovascular death , stroke , heart failure . AF lead activation renin-angiotensin system ( RAS ) , seem play important role atrial remodeling . Both experimental clinical data confirm pro-arrhythmic role RAS demonstrate anti-arrhythmic effect ACE- AT-I-Inhibitors . Madrid et al . show combination AT-I-Inhibitor irbesartan plus amiodarone decreased rate AF recurrence , dose-dependent effect , AF patient . ACE- AT-I-Inhibitors represent new efficient therapeutical option contrast nearly inevitable progression arrhythmia towards permanent form . Beta-Blockers common pharmacologic therapy AF patient . The aim BACE-PACE-Trial investigate preventive pacing stimulation ( PS ) vs. standard DDD [ R ] -60-Stimulation ( ST ) combination antiarrhythmic Beta-Blocker ACE-inhibitor therapy recurrence atrial fibrillation patient dual-chamber pacemaker The Responder ( patient without AF recurrence , respectively significant reduction AF burden ) compare standard stimulation . A clinically relevance meant reduction AF burden 25 % ( expert consensus ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Paroxysmal symptomatic atrial fibrillation Implantation dualchamber pacemaker generally accept pace indication Symptomatic sinus bradycardia , sinus arrest , TachyBradySyndrome Symptomatic sinuatrial block Advanced AVblock ( AV block II / III ) Binodal disease : Sicksinussyndrome advance AVblock AVNodalAblation combination pacemaker therapy ( `` Ablate &amp; Pace '' ) . The implantation fully functional DDDR Selection 9000 , Prevent AF , T 70 DR pacemaker ( Vitatron ) e.g . normal impedance , stimulation threshold sense value ) 2 4 month implantation Written inform consent patient Age &gt; 18 year Chronic heart failure ( NYHA III/IV ) Acute myocardial infarction &lt; 6 month Hypertrophic obstructive cardiomyopathy Symptomatic hypo hyperthyroidism Instable angina pectoris Cardiogenic shock Patients diabetes mellitus recurrent hypoglycaemia Pregnancy breast feed Participation clinical trial within last 30 day . Simultaneous participation registry ( e.g . project AB1 AFNET ) permit Reduced life expectancy ( &lt; 6 month ) Legal incapacity , circumstance would prevent patient understanding aim , nature extent clinical trial Evidence uncooperative attitude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Preventive stimulation</keyword>
	<keyword>Pacemaker</keyword>
</DOC>